Why is Concord Drugs falling/rising?

As of 02-Jul, Concord Drugs Ltd is experiencing a price increase, currently at Rs. 51.15, reflecting a rise of 1.68 or 3.4%. The stock has recently hit a new 52-week high of Rs. 53 and has shown strong performance, gaining 65% over the past week and outperforming its sector by 3.32%. The stock has been on a consecutive gain streak for the last five days, and it opened with a significant gain of 5.11% today. Despite some intraday volatility, the stock is trading above all major moving averages, indicating a strong upward trend. However, it is important to note that while the stock has generated a return of 32.34% over the past year, its profits have declined by 13%, which raises concerns about its long-term profitability.
In the broader market context, Concord Drugs has significantly outperformed the benchmark Sensex, which has only increased by 0.79% over the past week, while Concord's stock soared by 65%. This stark contrast highlights the stock's strong market performance in both the short and long term, as it has outperformed the BSE500 over various time frames. However, the company faces challenges, including weak long-term fundamental strength and a declining trend in operating profits, which could impact investor sentiment moving forward. Despite these concerns, the stock's attractive valuation relative to its peers and rising investor participation suggest a positive outlook in the near term.